scholarly journals Metabolic labelling of cancer cells with glycodendrimers stimulate immune-mediated cytotoxicity.

2021 ◽  
Author(s):  
David Goyard ◽  
Peremobowei Iyanu DIRIWARI ◽  
Nathalie Berthet
Keyword(s):  
Cancer Cells ◽  
Human Blood ◽  
Blood Stream ◽  
Metabolic Labelling ◽  
Immune Mediated ◽  
Immunotherapeutic Strategy

The recruitment of antibody naturally present in human blood stream at the surface of cancer cells have been proved a promising immunotherapeutic strategy to fight cancer. Antibody recruiting molecules (ARMs)...

scholarly journals Development of a bispecific immune engager using a recombinant malaria protein

2021 ◽  
Vol 12 (4) ◽  
Author(s):  
Mie A. Nordmaj ◽  
Morgan E. Roberts ◽  
Emilie S. Sachse ◽  
Robert Dagil ◽  
Anne Poder Andersen ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Immune Evasion ◽  
Blood Cells ◽  
Xenograft Model ◽  
Cancer Targeting ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Conjugation System ◽  
Immune Mediated

AbstractAs an immune evasion and survival strategy, the Plasmodium falciparum malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohydrate abundantly and exclusively present in the placenta. Cancer cells were found to share the same expression of this distinct carbohydrate, termed oncofetal chondroitin sulfate on their surface. In this study we have used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. Conjugation of these two proteins resulted in a single functional moiety that induced immune mediated killing of a broad range of cancer cells in vitro and facilitated tumor arrest in an orthotopic bladder cancer xenograft model.

scholarly journals STUDIES ON THE HEMOLYTIC STREPTOCOCCUS OF HUMAN ORIGIN

1935 ◽  
Vol 61 (4) ◽  
pp. 515-530 ◽  
Author(s):  
Hugh K. Ward ◽  
Champ Lyons
Keyword(s):  
Human Blood ◽  
Blood Stream ◽  
Streptococcal Infections ◽  
Human Origin ◽  
Common Variants ◽  
Hemolytic Streptococcus ◽  
Reliable Test ◽  
Laboratory Cultures

1. Four common variants of the hemolytic streptococcus of human origin have been described. These have been designated the F, M, attenuated M, and C variants. 2. The F and M variants only have been isolated from the blood stream in streptococcal infections. Only the M, however, has any primary virulence for the mouse. 3. Both these variants resist phagocytosis in human blood under suitable conditions, and this appears to be a reliable test for human virulence. 4. The attenuated M variant, found only in laboratory cultures, has a capsule as well developed as that of the virulent variants, and yet does not resist phagocytosis. 5. The C variant has no capsule and is readily phagocyted. It appears to correspond to the avirulent variant in other species. 6. An attempt has been made to correlate these four variants with those already described in the literature. 7. The application of these findings to the problem of virulence has been discussed.

SERS Analysis of Bacteria, Human Blood, and Cancer Cells: a Metabolomic and Diagnostic Tool

2014 ◽  
pp. 257-283 ◽  
Author(s):  
W. Ranjith Premasiri ◽  
Paul Lemler ◽  
Ying Chen ◽  
Yoseph Gebregziabher ◽  
Lawrence D. Ziegler
Keyword(s):  
Cancer Cells ◽  
Human Blood ◽  
Diagnostic Tool

Abstract 224: Enrichment and isolation of uncontaminated breast cancer cells from human blood samples

2015 ◽  
Author(s):  
Sandra V. Fernandez ◽  
Christopher Wagner ◽  
Zahida Parveen ◽  
Lucy Aburto ◽  
Carmela Paolillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Blood ◽  
Breast Cancer Cells ◽  
Blood Samples ◽  
Human Blood Samples

scholarly journals Evolving Concepts: Immunity in Oncology from Targets to Treatments

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Hina Khan ◽  
Rasim Gucalp ◽  
Iuliana Shapira
Keyword(s):  
Cancer Cells ◽  
Immune Checkpoint ◽  
Suppressive Effect ◽  
Anticancer Activities ◽  
Immune Balance ◽  
Immune Mediated ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Immune Ability ◽  
Immune Checkpoint Proteins

Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells. Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen-4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effector immune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.

Ovarian Cancer Cells Modulate Human Blood Neutrophils Response to ActivationIn Vitro

2008 ◽  
Vol 68 (3) ◽  
pp. 328-336 ◽  
Author(s):  
M. Klink ◽  
K. Jastrzembska ◽  
M. Nowak ◽  
K. Bednarska ◽  
M. Szpakowski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Human Blood ◽  
Ovarian Cancer Cells ◽  
Blood Neutrophils

scholarly journals Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight

2021 ◽  
Vol 23 (1) ◽  
pp. 254
Author(s):  
Michela Cortesi ◽  
Michele Zanoni ◽  
Francesca Pirini ◽  
Maria Maddalena Tumedei ◽  
Sara Ravaioli ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Cancer Cells ◽  
Cellular Senescence ◽  
Cell Types ◽  
Research Field ◽  
Ductal Adenocarcinoma ◽  
Immune Mediated ◽  
Current Therapies ◽  
Cancerous Cells

Pancreatic ductal adenocarcinoma (PDAC) has one of the most dismal prognoses of all cancers due to its late manifestation and resistance to current therapies. Accumulating evidence has suggested that the malignant behavior of this cancer is mainly influenced by the associated strongly immunosuppressive, desmoplastic microenvironment and by the relatively low mutational burden. PDAC develops and progresses through a multi-step process. Early in tumorigenesis, cancer cells must evade the effects of cellular senescence, which slows proliferation and promotes the immune-mediated elimination of pre-malignant cells. The role of senescence as a tumor suppressor has been well-established; however, recent evidence has revealed novel pro-tumorigenic paracrine functions of senescent cells towards their microenvironment. Understanding the interactions between tumors and their microenvironment is a growing research field, with evidence having been provided that non-tumoral cells composing the tumor microenvironment (TME) influence tumor proliferation, metabolism, cell death, and therapeutic resistance. Simultaneously, cancer cells shape a tumor-supportive and immunosuppressive environment, influencing both non-tumoral neighboring and distant cells. The overall intention of this review is to provide an overview of the interplay that occurs between senescent and non-senescent cell types and to describe how such interplay may have an impact on PDAC progression. Specifically, the effects and the molecular changes occurring in non-cancerous cells during senescence, and how these may contribute to a tumor-permissive microenvironment, will be discussed. Finally, senescence targeting strategies will be briefly introduced, highlighting their potential in the treatment of PDAC.

Sign in / Sign up

Export Citation Format

Share Document